ClinicalTrials.gg
RecruitingNCT07447895Updated Apr 23, 2026

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

An interventional study of Pelvic floor physical therapy in Cervical Cancer, Radiation Therapy Complication and Pelvic Floor Disorders, sponsored by University of Cincinnati. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by University of Cincinnati · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
492nd of 678
28 · median 71
Started
2026
with 29 others
No phase
246 of 834
51 open now
Primary completion
2029-04
later than 185 of 217 live
Registered
820th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 492nd largest by planned enrollment of the 678 interventional ones that give a count, is one of 30 that started in 2026, is one of 246 with no phase, reaches primary completion later than 185 of the 217 other live ones, and was the 820th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

137 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a single arm phase II study in which 28 patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy.

Read the detailed description

This is a single arm phase II study in which 28 patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy. The objective is to determine the rate of fecal incontinence at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. The primary endpoint of this study is the rate of fecal incontinence at 3 months after RT utilizing the EORTC-QLQ CX24 validated survey. A score of 1 or higher will be classified as having incontinence.

03

Conditions studied

  • Cervical Cancer
  • Radiation Therapy Complication
  • Pelvic Floor Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be female.
  2. Patients must be 18 years old or older.
  3. Any patient with invasive cervical cancer who is planned for definitive chemoradiation.
  4. Plan to receive a minimum dose of 45Gy to pelvis per investigator.
  5. Willing to undergo pelvic floor physical therapy.

Exclusion criteria

Exclusion Criteria:

  1. Any previous therapeutic pelvic radiation.
  2. Non-English speaking.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Pelvic floor physical therapy

    Patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy.

    Procedure: Pelvic floor physical therapy

Interventions

  • ProcedurePelvic floor physical therapy

    Four weeks after completion of RT, patients will begin a standardized pelvic floor PT course. The protocol will include two 1-hour physical therapy appointments focused on pelvic floor muscle training, dilator training and education. These sessions will be 4 weeks apart and performed by a pelvic floor physical therapist.

06

What researchers measure

Primary outcomes

  1. Evaluate fecal incontinence via EORTC-QLQ CX24 validated survey

    To determine the rate of fecal incontinence at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. The primary endpoint of this study is the rate of fecal incontinence at 3 months after RT utilizing the EORTC-QLQ CX24 validated survey. A score of 1 or higher will be classified as having incontinence.

    Time frame: 3 months after Radiation Therapy Treatment

Secondary outcomes

  1. Rates of urinary incontinence via EORTC-QLQ CX24

    1\. To determine the rates of urinary incontinence 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. a. Secondary endpoints will include rates of urinary incontinence as obtained from the EORTC-QLQ CX24 at 3-months post-treatment.

    Time frame: 3 months after Radiation Therapy Treatment

  2. Sexual symptoms via EORTC-QLQ CX24

    1\. To determine sexual symptoms at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. a. Secondary endpoints will include rates of sexual symptoms as obtained from the EORTC-QLQ CX24 at 3-months post-treatment.

    Time frame: 3 months after Radiation Therapy Treatment

  3. QOL as obtained from the EORTC-QLQ CX24

    1\. To determine QOL at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. a. Secondary endpoints will include QOL as obtained from the EORTC-QLQ CX24 at 3-months post-treatment.

    Time frame: 3 months after Radiation Therapy Treatment

  4. Compliance rates with recommended standard of care schedule of dilator via self reports

    2\. To determine compliance rates with recommended standard of care schedule of dilator use at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. 1. Participant reported compliance with home exercise course from baseline through 3 months will be collected and analyzed for rate of compliance against protocol usage. 2. Reported dilator compliance will be compared to reported historical compliance rates for this SOC recommendation

    Time frame: 3 months after Radiation Therapy Treatment

  5. Evaluate changes in pelvic floor muscle function using the validated Brink scale

    3\. To evaluate changes in pelvic floor muscle function at 3 months after RT in women undergoing pelvic radiation for gynecologic malignancies. a. Descriptive analysis of pelvic floor muscle function (strength, coordination, endurance objectively graded using the validated Brink scale) at baseline and follow up, along with participant reported compliance with home exercise course will also be collected and reported.

    Time frame: At Baseline and at 3 months after Radiation Therapy Treatment

07

Study locations

1 of 1 sites recruiting
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
    Recruiting
    • UCCC Clinical Trials Office · Contact
    • Sarah Sittenfeld · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2029, 36 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 36 months is close to that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 4, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Apr 16, 2029
CompletionEst.
Apr 16, 2030
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447895
Responsible party
Sarah Sittenfeld (Principal Investigator, University of Cincinnati) — Principal investigator
First posted
Mar 4, 2026
Start date
Apr 16, 2026
Primary completion
Apr 16, 2029 (estimated)
Completion
Apr 16, 2030 (estimated)
Last update
Apr 23, 2026

Study contacts

UCCC Clinical Trials Office
Contact
cancer@uchealth.com
513-584-7698
Sarah Sittenfeld
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion